CAS ID: | 139755-83-2 |
Molecular Formula: | C22H30N6O4S |
Molecular Weight: | 474.6 g/mol |
Monoisotopic Mass: | 474.2049 g/mol |
Class: | Small Molecule |
Natural Product: | No |
Other Names: | VIZARSIN | REVATIO | UK-92480 | SILDENAFIL CITRATE | NIPATRA | UK-92480-10 | SILDENAFIL | UK-92,480-10 | VIAGRA |
Analysis: | Drug repositioning mechanism analysis |
InChI: | InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29) | See All |
InChI Key: | BNRNXUUZRGQAQC-UHFFFAOYSA-N | |
Smiles: | CCCc1nn(C)c2C(=O)NC(=Nc12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4 | See All |
Molfile: | Download |
Reference Record 1
Reference Record 2
PubMed ID | 25416030 | Target ID | T0431 |
Uniprot ID | cGMP-specific 3',5'-cyclic phosphodiesterase | Name | cGMP-specific 3',5'-cyclic phosphodiesterase |
Model | vitro,mice | Fibrosis Disease | Cardiac fibrosis |
Process I | |||
Process II | fibroblasts proliferation | ||
Process III | prevenet collagen deposition | ||
Mechanism | Targeting CBP1 |
Trial Record 1
ClinicalTrial ID | NCT02057458 | Disease | Cystic fibrosis |
Phase | Phase 2 | Status | Completed |
First Received | February 7, 2014 | Last Verified | January 9, 2019 |
Sponsor | Augusta University |
Trial Record 2
ClinicalTrial ID | NCT00981747 | Disease | Idiopathic pulmonary fibrosis |
Phase | Phase 2,Phase 3 | Status | Terminated |
First Received | September 22, 2009 | Last Verified | November 12, 2018 |
Sponsor | Alicia Gerke |
Trial Record 3
ClinicalTrial ID | NCT02802345 | Disease | Idiopathic pulmonary fibrosis |
Phase | Phase 3 | Status | Completed |
First Received | June 16, 2016 | Last Verified | January 11, 2019 |
Sponsor | Boehringer Ingelheim |
Trial Record 4
ClinicalTrial ID | NCT00352482 | Disease | Pulmonary fibrosis |
Phase | Phase 2 | Status | Completed |
First Received | July 14, 2006 | Last Verified | July 29, 2016 |
Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
Trial Record 5
ClinicalTrial ID | NCT02951429 | Disease | Idiopathic pulmonary fibrosis |
Phase | Phase 2 | Status | Active, not recruiting |
First Received | November 1, 2016 | Last Verified | January 16, 2019 |
Sponsor | Hoffmann-La Roche |
Trial Record 6
ClinicalTrial ID | NCT00659529 | Disease | Cystic fibrosis |
Phase | Phase 1,Phase 2 | Status | Completed |
First Received | April 16, 2008 | Last Verified | April 26, 2017 |
Sponsor | National Jewish Health |
Trial Record 7
ClinicalTrial ID | NCT02626182 | Disease | Cystic fibrosis |
Phase | Phase 1,Phase 2 | Status | Completed |
First Received | December 10, 2015 | Last Verified | February 7, 2018 |
Sponsor | National Jewish Health |
Trial Record 8
ClinicalTrial ID | NCT01132482 | Disease | Cystic fibrosis |
Phase | Phase 2 | Status | Completed |
First Received | May 28, 2010 | Last Verified | March 19, 2019 |
Sponsor | National Jewish Health |
Trial Record 9
ClinicalTrial ID | NCT00625079 | Disease | Idiopathic pulmonary fibrosis |
Phase | Phase 4 | Status | Withdrawn |
First Received | February 28, 2008 | Last Verified | May 1, 2018 |
Sponsor | University of California, Los Angeles |
Trial Record 10
ClinicalTrial ID | NCT00359736 | Disease | Idiopathic pulmonary fibrosis |
Phase | Phase 2 | Status | Completed |
First Received | August 2, 2006 | Last Verified | November 1, 2017 |
Sponsor | VA Office of Research and Development |
Trial Record 11
ClinicalTrial ID | NCT01194232 | Disease | Liver fibrosis |
Phase | Phase 1,Phase 2 | Status | Withdrawn |
First Received | September 2, 2010 | Last Verified | December 11, 2012 |
Sponsor | Children's Hospital Medical Center, Cincinnati |
Trial Record 12
ClinicalTrial ID | NCT01382368 | Disease | Idiopathic pulmonary fibrosis |
Phase | Phase 4 | Status | Unknown |
First Received | June 27, 2011 | Last Verified | November 15, 2012 |
Sponsor | Rabin Medical Center |
Trial Record 13
ClinicalTrial ID | NCT01954524 | Disease | Liver fibrosis |
Phase | Phase 1 | Status | Terminated |
First Received | October 1, 2013 | Last Verified | September 27, 2017 |
Sponsor | University of Maryland |